CFTR CRISPR/Cas9 gene therapy (Editas Medicine)

N/A

Report date: 2025/03/18 18:04:59

Base Information

Drug NameCFTR CRISPR/Cas9 gene therapy (Editas Medicine)

Drug Alias NameN/A

ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9Cell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector

Mechanisms of ActionCystic fibrosis transmembrane conductance regulator modulators

TargetsCystic fibrosis transmembrane conductance regulator

Therapy Area/IndicationsCystic Fibrosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesEditas Medicine Inc

China Registration ClassN/A

Develop Information

Active CompaniesEditas Medicine Inc

Inactive CompaniesN/A

Active IndicationsCystic Fibrosis

Inactive IndicationsN/A

Other Information

ATC CodeN/A